Granted Patent
B2
US 12,544,404 · App. 17/277,093 · Granted Feb 10, 2026
Compositions and methods for treating bone injury
A61K35/14A61K9/0024A61K35/16A61K35/18A61K35/19A61K38/1825A61K38/1866A61K38/1875A61K38/36A61K38/4813A61K38/482A61K38/4833A61K47/02A61K47/12A61L27/225A61L27/227A61L27/3616A61L27/446A61L27/56A61P19/08A61L2300/254A61L2300/414A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure relates to compositions and methods of treating, improving, and accelerating the healing of large segmental bone defects in a subject. The method comprises administering to a patient in need of treatment an effective amount of whole blood, sodium citrate, ecarin and BMP-2.
Claims (13)
1 . A composition consisting of: (a) isolated whole blood; (b) sodium citrate; (c) thrombin and calcium chloride; and (d) bone morphogenetic protein 2 (BMP-2).
2 . The composition of claim 1 , wherein the whole blood comprises viable cells and one or more biological factors.
3 . The composition of claim 2 , wherein about 50% to 70% of the viable cells of the whole blood remain viable after formation of the hematoma.
4 . The composition of claim 1 , wherein the dose of BMP-2 present in the composition is at least 0.01 mg.
5 . The composition of claim 1 , wherein the composition is formulated as a gel or a liquid.
6 . A method of promoting bone healing or producing bone replacement material or implants, the method comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 1 .
7 . The method of claim 6 , wherein the amount of BMP-2 present in the composition is at least 0.01-5 mg.
8 . The method of claim 6 , wherein the subject has a skeletal defect.
9 . The method of claim 6 , wherein the subject has one or more bone injuries.
10 . A method of constructing an implant, the method comprising: a) dimensioning a depot implant in at least one of a shape and a size that facilitates implantation of the depot implant into a bone defect; and b) structuring the depot implant to have a scaffold by introducing (i) isolated whole blood and sodium citrate; (ii) thrombin and calcium chloride; and (iii) bone morphogenetic protein 2 (BMP-2) to create the scaffold; wherein the scaffold has a porosity of 55 to 75%.
11 . The method of claim 10 , wherein the scaffold is constructed as a clot.
12 . The method of claim 10 , further comprising one or more growth factors, wherein the one or more growth factors is BMP-7, BMP-4, BMP-6, BMP-9, BMP-14, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), or a combination thereof.
13 . The method of claim 10 , wherein the amount of BMP-2 present in the scaffold is at least 0.01 mg.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 26, 2021
From: GLATT, VAIDA
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 056361/0451 →
Continuity (3)
Provisional Application
62845500
· May 9, 2019
Provisional Application
62732534
· Sep 17, 2018
References Cited (125)
US 7348411B2
· Petrescu
· 2008
[cited by applicant]
US 7955603B2
· Richardson et al.
· 2011
[cited by applicant]
US 8197840B2
· Vukicevic et al.
· 2012
[cited by applicant]
US 9320653B2
· Vournakis et al.
· 2016
[cited by applicant]
US 20100028311A1
· Motlagh
· 2010
[cited by examiner]
US 20120190832A1
· Herr et al.
· 2012
[cited by applicant]
US 20140271610A1
· San Antonio
· 2014
[cited by examiner]
US 20170128617A1
· DeAnglis
· 2017
[cited by examiner]
AU 2019344801
· 2021
[cited by applicant]
CA 3113691
· 2021
[cited by applicant]
CN 2019800692770
· 2021
[cited by applicant]
EP 2049040B1
· 2013
[cited by applicant]
EP 198613895
· 2021
[cited by applicant]
EP 2019861389
· 2021
[cited by applicant]
JP 2010505766A
· 2010
[cited by applicant]
JP 2021539484
· 2021
[cited by applicant]
KR 1020217010893
· 2021
[cited by applicant]
WO WO1996003432A1
· 1996
[cited by applicant]
WO WO1996017633A1
· 1996
[cited by applicant]
WO WO2002000272A2
· 2002
[cited by applicant]
WO WO2007092147A2
· 2007
[cited by applicant]
WO WO2008011192A2
· 2008
[cited by applicant]
WO WO2017083248A1
· 2017
[cited by applicant]
WO WO2019076484A1
· 2019
[cited by applicant]
WO PCTUS2019051541
· 2019
[cited by applicant]
Shehter-Harkavyk, et al., On the Relationship between the adhesive properties and the structural features of fibrin sealants, 2004, J. Adhesion Sci. Technol., vol. 18, No. 12, 1415-1425 (Year: 2004).
[cited by examiner]
U.S. Appl. No. 62/732,534, filed Sep. 17, 2018, Vaida Glatt.
[cited by applicant]
U.S. Appl. No. 62/845,500, filed May 9, 2018, Vaida Glatt.
[cited by applicant]
Noori, A., et al. A review of fibrin and fibrin composites for bone tissue enginerring. International Journal of Nanomedicine. 2017; 12: 4937-4961.
[cited by applicant]
Pretorius, E., et al. Comparative Scanning Electron Microscopy of Platelets and Fibrin Networks of Human and Differents Animals. Int. J. Morphol. 2009; 27(1): 69-76.
[cited by applicant]
Van Rooy, et al. Platelet hyperactivity and fibrin clot structure in transient ischemic attack individuals in the presence of metabolic syndrome: a microscopy and thromboelastography study. Cardiovascular Diabetology. 2…
[cited by applicant]
Badami AS et al. Effect of fiber diameter on spreading, proliferation, and differentiation of osteoblastic cells on electrospun poly(lactic acid) substrates. Biomaterials. 2006;27: 596-606.
[cited by applicant]
Belmont Jr. PJ, et al. Combat wounds in Iraq and Afghanistan from 2005 to 2009. J Trauma Acute Care Surg. 2012;73: 3-12.
[cited by applicant]
Bovill EG, et al. Evidence that meizothrombin is an intermediate product in the clotting of whole blood. Arterioscler Thromb Vasc Biol. 1995;15: 754-758.
[cited by applicant]
Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008; 25: 475-516.
[cited by applicant]
Busenlechner D, et al. Sinus augmentation analysis revised: the gradient of graft consolidation. Clin Oral Implants Res. 2009;20: 1078-1083.
[cited by applicant]
Carlisle CR, et al. The mechanical stress-strain properties of single electrospun collagen type I nanofibers. Acta Biomater. 2010; 6: 2997-3003.
[cited by applicant]
Carragee EJ, et al. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11: 471-491.
[cited by applicant]
Chernysh IN, et al. Fibrin clots are equilibrium polymers that can be remodeled without proteolytic digestion. Sci Rep. 2012;2: 879.
[cited by applicant]
Choi B-H, et al. Effect of platelet-rich plasma on bone regeneration in autogenous bone graft. Int J Oral Maxillofac Surg. 2004;33: 56-9.
[cited by applicant]
Choukroun J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part V: histologic evaluations of PRF effects on bone allograft maturation in sinus lift. Oral Surg Oral Med Oral Pathol Oral Rad…
[cited by applicant]
Diesen DL and Lawson JH. Bovine thrombin: history, use, and risk in the surgical patient. Vascular. 2008;16: S29-36.
[cited by applicant]
Eichhorn SJ and Sampson WW. Statistical geometry of pores and statistics of porous nanofibrous assemblies. J R Soc Interface. 2005;2: 309-318.
[cited by applicant]
Enneking WF and Campanacci DA. Retrieved human allografts: a clinicopathological study. J Bone Joint Surg Am. 2001;83(7):971-986.
[cited by applicant]
Fischer H. A Guide to U.S. Military Casualty Statistics: Operation Freedom's Sentinel, Operation Inherent Resolve, Operation New Dawn, Operation Iraqi Freedom, and Operation Enduring Freedom. Congr Res Serv. 2015; 7.
[cited by applicant]
Gabriel DA, et al. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267: 24259-63.
[cited by applicant]
Gantenbein-Ritter B, et al. Confocal imaging protocols for live/dead staining in three-dimensional carriers. Methods Mol Biol. 2011;740: 127-40.
[cited by applicant]
Glatt V, et al. Reverse Dynamization: Influence of Fixator Stiffness on the Mode and Efficiency of Large-Bone-Defect Healing at Different Doses of rhBMP-2. J Bone Joint Surg Am. 2016;98: 677-87.
[cited by applicant]
Glatt V et al. Design, characterisation and in vivo testing of a new, adjustable stiffness, external fixator for the rat femur. Eur Cell Mater. 2012;23: 289-98; discussion 299.
[cited by applicant]
Glatt V, et al. Improved healing of large segmental defects in the rat femur by reverse dynamization in the presence of bone morphogenetic protein-2. J Bone Joint Surg Am. Nov. 21, 2012;94(22):2063-73.
[cited by applicant]
Glatt V and Matthys R. Adjustable stiffness, external fixator for the rat femur osteotomy and segmental bone defect models. J Vis Exp. 2014:e51558.
[cited by applicant]
Han SM, et al. Efficacy and safety of alfimeprase in patients with acute peripheral arterial occlusion (PAO). J Vasc Surg. 2010;51: 600-9.
[cited by applicant]
He L, et al. A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surgery, Oral Med Oral Pathol Oral Radio…
[cited by applicant]
Hernandez-Fernandez A, et al. Effect of administration of platelet-rich plasma in early phases of distraction osteogenesis: an experimental study in an ovine femur model. Injury. 2013;44: 901-7.
[cited by applicant]
Hong T-T, et al. Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase, Am J Physiol Heart Circ Physiol. 2006;290: H959-67.
[cited by applicant]
Huntington JA. Thrombin plasticity. Biochim Biophys Acta—Proteins Proteomics. 2012;1824: 246-252.
[cited by applicant]
Hutton R. Action of snake venom components on the haemostatic system. Blood Rev. 1993;7(3): 176-189.
[cited by applicant]
Iqbal J, et al. Platelet-rich plasma for the replenishment of bone. Curr Osteoporos Rep. 2011;9: 258-263.
[cited by applicant]
Kanakaris NK, Giannoudis PV. The health economics of the treatment of long-bone non-unions. Injury. 2007; 38 Suppl 2: S77 S84.
[cited by applicant]
Kang TS, et al. Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. FEBS J. 2011;278: 4544-76.
[cited by applicant]
Kaur S, et al. Influence of electrospun fiber size on the separation efficiency of thin film nanofiltration composite membrane, J Memb Sci. 2012; 392-393: 101-111.
[cited by applicant]
Khan SN, et al. The biology of bone grafting. J Am Acad Orthop Surg. 2005;13: 77-86.
[cited by applicant]
King GF. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin Biol Ther. 2011; 11:1469-84.
[cited by applicant]
Krishnaswamy S, et al. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem. 1986; 261: 8977-8984.
[cited by applicant]
Kurikchy MQ, et al. Histological evaluation of bone healing using organic bovine bone in combination with platelet-rich plasma (an experimental study on rabbits). Clin Oral Investig. 2013;17: 897-904.
[cited by applicant]
Lai BFL, et al. The influence of poly-N-[(2,2-dimethyl-1,3-dioxolane)methyl]acrylamide on fibrin polymerization, cross-linking and clot structure. Biomaterials. Elsevier Ltd; 2010;31: 5749-5758.
[cited by applicant]
Li H, et al. Anterior lumbar interbody fusion with carbon fiber cage loaded with bioceramics and platelet-rich plasma. An experimental study on pigs. Eur Spine J. 2004;13: 354-8.
[cited by applicant]
Liu W, et al. Electrospun nanofibers for regenerative medicine. Adv Healthc Mater. 2012; 1: 10-25.
[cited by applicant]
Maes C, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell;2010;19: 329-344.
[cited by applicant]
Marx RE, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Platelet-rich plasma: Growth factor enhancement for bone grafts. 1998;85: 638-46.
[cited by applicant]
Marden LJ, et al. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J Clin Invest. 1993; 92: 2897-2905.
[cited by applicant]
Mckee Md. Management of segmental bony defects: the role of osteoconductive orthobiologics. J Am Acad Orthop Surg. 2006;14: S163-7.
[cited by applicant]
Meier J and Stocker K. Effects of snake venoms on hemostasis. Crit Rev Toxicol. 1991;21: 171-182.
[cited by applicant]
Nezafati et al., Comparison of pedicled buccal fat pad flap with buccal flap for closure of oro-antral communication; Int J Oral Maxillofac Surg. 2012; 41(5):624-8.
[cited by applicant]
Ofosu FA, et al. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Clin Ther. 2009;31(4): 679-691.
[cited by applicant]
Oryan A, et al. Platelet-rich plasma for bone healing and regeneration. Expert Opin Biol Ther. 2016;16: 213-32.
[cited by applicant]
Pham QP, et al. Electrospun poly(epsilon-caprolactone) microfiber and multilayer nanofiber/microfiber scaffolds: characterization of scaffolds and measurement of cellular infiltration. Biomacromolecules. 2006;7: 2796-28…
[cited by applicant]
Pollak AN and Ficke Jr, Extremity War Injuries Ill Session Moderators. Extremity war injuries: challenges in defmitive reconstruction. J Am Acad Orthop Surg. 2008;16: 628-34.
[cited by applicant]
Probst A and Spiegel H-U. Cellular mechanisms of bone repair. J Investig Surg. 1997;10: 77-86.
[cited by applicant]
Pryor ME, et al. Analysis of rat calvaria defects implanted with a platelet-rich plasma preparation: radiographic observations. J Periodontol. 2005;76: 1287-1292.
[cited by applicant]
Ranly DM, et al. Platelet-rich plasma inhibits demineralized bone matrix-induced bone formation in nude mice. J Bone Joint Surg Am. 2007;89: 139-147.
[cited by applicant]
Sanchez AR, et al. Regenerative potential of platelet-rich plasma added to xenogenic bone grafts in peri-implant defects: a histomorphometric analysis in dogs. J Periodontol. 2005; 76: 1637-1644.
[cited by applicant]
Sanchez EF, et al. Chimeric fibrolase: covalent attachment of an RGD-like peptide to create a potentially more effective thrombolytic agent. Thromb Res. 1997; 87: 289-302.
[cited by applicant]
Sands JJ, et al. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis. 2000; 35(5): 796-801.
[cited by applicant]
Simman R, et al. Role of platelet-rich plasma in acceleration of bone fracture healing. Ann Plast Surg. 2008;61: 337-44.
[cited by applicant]
Soffer E, et al. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. Fibrin sealants and platelet preparations in bone and periodontal healing. 2003. 95(5): 521-528.
[cited by applicant]
Stansbury LG, et al. Amputations in U.S. military personnel in the current conflicts in Afghanistan and Iraq. J Orthop Trauma. 2008; 22: 43-46.
[cited by applicant]
St. Pierre L, et al. Comparative analysis of prothrombin activators from the venom of Australian elapids. Mol Biol Evol. 2005;22: 1853-1864.
[cited by applicant]
Swenson S, et al. Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation. Arch Biochem Biophys. 2000; 384: 227-37.
[cited by applicant]
Takeya H, et al. Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains. J Biol Chem. 1…
[cited by applicant]
Thibault L, et al. Characterization of blood components prepared from whole-blood donations after a 24-hour hold with the platelet-rich plasma method. Transfusion. 2006;46: 1292-1299.
[cited by applicant]
Tokunaga F, et al. The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences. J Biol Chem. 1988; 263: 174…
[cited by applicant]
Urist MR. Bone morphogenetic protein: the molecularization of skeletal system development. J Bone Miner Res. 1997;12: 343-6.
[cited by applicant]
Van Rooy, et al. Platelet hyperactivity and fibrin clot structure in transient ischemic attack individuals in the presence of metabolic syndrome: a microscopy and thromboelastography® study. Cardiovascular Diabetology, …
[cited by applicant]
Wang X, et al. Alteration of blood clot structures by interleukin-1 beta in association with bone defects healing. Sci Rep; 2016;6: 35645.
[cited by applicant]
Wang X, et al. Structural properties of fracture haematoma: current status and future clinical implications. J Tissue Eng Regen Med. 2017; 11(10): 2864-2875.
[cited by applicant]
Weiner BK and Walker M. Efficacy of autologous growth factors in lumbar intertransverse fusions. Spine (Phila Pa 1976). 2003;28:17 1968-1971.
[cited by applicant]
Weisel JW and Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood. 2013; 121: 1712-1719.
[cited by applicant]
Wheeler DL, et al. Biomechanical evaluation of retrieved massive allografts: preliminary results. Biomed Sci Instrum. 2001; 37: 251-256.
[cited by applicant]
Wolberg AS and Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008;38: 15-23.
[cited by applicant]
Wu, et al. Economic burden of illness among US patients experiencing fracture nonunion, Orthopedic Research and Reviews. 2013(5):21-31.
[cited by applicant]
Yasko AW, et al. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg Am. The America…
[cited by applicant]
Zura, et al., Epidemiology of Fracture Nonunion in 18 Human Bones. JAMA Surg. Nov. 16, 2016;151(11):e162775.
[cited by applicant]
International Search Report and Written Opinion were mailed on Jan. 17, 2020 by the International Searching Authority for International Application No. PCT/US2019/051541, filed on Sep. 17, 2019 and published as WO/2020/…
[cited by applicant]
International Preliminary Report on Patentability was mailed on Mar. 9, 2021 by the International Searching Authority for International Application No. PCT/US2019/051541, filed on Sep. 17, 2019 and published as WO/2020/…
[cited by applicant]
Isobe, K., et al. Platelet-rich fibrin prepared from stored whole-blood samples. International Journal of Implant Dentistry. 2017;3:6-1.
[cited by applicant]
Kawase, T. Platelet-rich plasma and its derivatives as promising bioactive materials for regenerative medicine: basic principles and concepts underlying recent advances. Odontology. 2015;103:126-135.
[cited by applicant]
Paletta, GA, et al. The repair of osteochondral defects using an exogenous fibrin clot. An experimental study in dogs. The American Journal of Sports Medicine. 1992;20(6):725-731.
[cited by applicant]
Brkljacic, et al., “Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity,” International Orthopaedics (SICOT) 37:529-541 (2013).
[cited by applicant]
AGES Report 2016.
[cited by applicant]
Brkljacic, et al. “Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity”, 37(3): 529-41; Int Orthop, 2013.
[cited by applicant]
Dumic-Cule, et al. “Bone morphogenetic proteins in fracture repair,” Int Orthop, 42(11): 2619-2626, 2018.
[cited by applicant]
MHRA Scientific Advice, Ref: 614/Recombinant human bone morphogenetic protein 6 (BMP6), Jun. 2014.
[cited by applicant]
Nowak, G. et al. “The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors,” Pathophysiology. 173-183, 2003/2004.
[cited by applicant]
Shehter-Harkavyk and Bianco-Peled, “On the relationship between the adhesive properties and the structural features of fibrin sealants”, Journal of Adhesion Science and Technology, vol. 18, 2004—Issue 12, pp. 1415-1425,…
[cited by applicant]
Song, et al. Identification of a Key Residue Mediating Bone Morphogenetic Protein (BMP)-6 Resistance to Noggin Inhibition Allows for Engineered BMPs with Superior Agonist Activity, J. Biol Chem, vol. 285, Issue 16, P121…
[cited by applicant]
Vukicevic, et al. “The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing,” Int Orhop, 38(3): 635-47, 2014.
[cited by applicant]